Background: The present study was motivated by the need to design a safe nano-carrier for the delivery of doxorubicin which could be tolerant to normal cells. PCL 63 -b-PNVP 90 was loaded with doxorubicin (6 mg/ml), and with 49.8% drug loading efficiency; it offers a unique platform providing selective immune responses against lymphoma.
Introduction
Adriamycin or Doxorubicin (DOX) hydrochloride, an anthracycline antibiotics is considered as the most effective chemotherapeutics used for the treatment of cancers including acute lymphoblastic and myelogenous leukemia, sarcomas, pediatric solid tumors, non-Hodgkin's and Hodgkin's lymphoma, neuroblastoma, and carcinomas of breast, ovaries and thyroid. The cytotoxic effects of DOX include DNA double helix intercalation, inhibition of topoisomerase II, production of reactive oxygen species (ROS), mitochondrial dysfunction, induction of p53, and activation of caspases [1, 2] . However, its short biological life span, nonspecific distribution, development of drug resistance and severe cardiac toxicity including development of cardiomyopathy, have restricted its success [3] . Several polymer based delivery systems like polymeric micelles [4] , synthetic polymer conjugates [5] , and antibody targeted carriers [6] have been designed to reduce or alter toxicity in organs like heart, and enhances its potential to the site of drug actions like tumors. Yet the therapeutic efficacy of these formulations has not been demonstrated although modest increase has been reported in certain cases. The versatility of Poly-(e-caprolactone) (PCL) as a model polymer for pharmaceutical formulations along with functionalization features have been demonstrated over the past decade justifies its immense usefulness [7] . PCL modifications could provide better flexibility including modifications in drug release pattern, micellar drug delivery, tissue compatibility and circumvention of multi drug resistance [8] . Amphiphilic block copolymers have both hydrophobic and hydrophilic segments and undergoes self-assembly, which give rise to its typical aqueous solution and dispersion properties.
Amphiphilic block copolymers containing hydrophilic poly (Nvinylpyrrolidone) (PNVP) segment have several biologically important criteria's including high water solubility, low toxicity, biocompatibility, complexation capability, cryo-protectivity, lypoprotectivity and anti biofouling properties. Very few reports of the synthesis and characterization of amphiphilic block copolymers containing a biocompatible hydrophilic poly (N-vinylpyrrolidone) (PNVP) block and a biodegradable and biocompatible hydrophobic poly (e-caprolactone) (PCL) block, prepared via conventional radical polymerization of N-vinylpyrrolidone (NVP) are available in the literature [9] [10] [11] . Recently, Jeon et al. have reported the synthesis and characterization of well-defined amphiphilic PNVPb-PCL block copolymers prepared through the combination of cobalt-mediated controlled radical polymerization of NVP and controlled ROP of CL [12] . We have recently reported the synthesis of well-defined amphiphilic block copolymers of CL and NVP by combining the controlled ROP of CL and the controlled metal-free xanthate-mediated RAFT polymerization of NVP. Selfassembly behavior of the obtained amphiphilic block copolymers was studied in details using 1 H NMR, TEM, fluorescence spectroscopy, and light scattering [13] .
Herein, we report the synthesis of a PCL-based amphiphilic polymeric nano delivery system DOX-PCL 63 -b-PNVP 90 , which is highly efficient in delivering DOX to tumor targets and also showed enhanced performance in DOX resistant forms as well. DOX-PCL 63 -b-PNVP 90 is significantly less toxic compared to free DOX against various cell subsets including lymphocytes, which are specifically susceptible to doxorubicin mediated death. DOX-PCL 63 -b-PNVP 90 prolonged the survival of tumor bearing mice compared to free DOX and restricts the metastasis of lymphoma to other organs. Besides that, DOX-PCL 63 -b-PNVP 90 prevents the accumulation of doxorubicin in targeted organs like heart compared to free DOX, suggesting its unique suitability for therapeutic purposes against lymphoma.
Materials and Methods

Reagents
Triethylamine (TEA) (Loba Chemie, Mumbai, India, 99%), 2-bromopropionyl bromide (Fluka, Israel, .97%), stannous 2-ethylhexanoate [Sn(Oct) 2 ] (Aldrich, St Louis, USA, 99%), diethyl ether (s.d.fine, Mumbai, India), hexane (CDH, Mumbai, India), methanol (Loba Chemie, Mumbai, India, 99%), sodium hydrogen carbonate (Loba Chemie, Mumbai, India), ammonium chloride (s.d.fine, Mumbai, India), anhydrous magnesium sulfate (Loba Chemie, Mumbai, India) were used as received. Benzyl alcohol (s.d.fine, Mumbai, India, 99%) was dried over CaO and then distilled under reduced pressure. e-Caprolactone (CL) (Aldrich, St Louis, USA, 99%) was dried over calcium hydride (CaH 2 ) for 48 h at room temperature and then distilled under reduced pressure before use. N-Vinylpyrrolidone (Aldrich, St Louis, USA, 99%) was dried over anhydrous magnesium sulfate and distilled under reduced pressure. 2, 2 / -Azobis (isobutyronitrile) (AIBN) (Spectrochem, Mumbai, India, 98%) was recrystallized from methanol. Tetrahydrofuran (THF) (Loba Chemie, Mumbai, India) was dried and fractionally distilled from sodium and benzophenone. Ethanol (Saraya Distilliary, India) was stirred over CaO overnight and distilled over fresh CaO. Potassium O-ethyl xantate was prepared according to our previous work [14] . PCL 63 -b-PNVP 90 was synthesized according to our recently published method [13] . Doxorubicin (Adriamycin) was purchased from Selleckchem (S1208) South Loop West, Suite 225, Houston, TX 77054, USA. RPMI 1640, penicillin and streptomycin were purchased from GIBCO, Invitrogen, Carlsbad, CA and fetal bovine serum from Hyclone, Logan, UT. Hoechst 33342 was purchased from Himedia, India. Annexin V Apoptosis Detection Kit (sc-4252 AK) was purchased from Santa Cruz Biotechnology, Dallas, TX, U.S.A. Other general & fine chemicals unless otherwise stated were purchased from SIGMA-ALDRICH, St. Louis, MO, USA.
Cell Lines and Cell Culture
Dalton lymphoma (DL) was maintained in the peritoneum of AKR (H2k) mice by periodic transfer of tumor cells via intraperitoneal injection [15, 16] . Human erytholeukemic cell line K-562, T cell leukemia line JE6.1, and Burkitt lymphoma cell line Raji were kind gift of Dr. Santu Bandyopadhyay, IICB, Kolkata. The cell lines were originally obtained from American Type Culture Collection (ATCC), Manahass, USA. The cells were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA), henceforth, called as complete medium. The cell lines used in the study were free from mycoplasma. To generate DOX-resistant (DOX-R) cell lines like K-562/DOX-R, JE6.1/ DOX-R, Raji/DOX-R, and DL/DOX-R, parental K-562, JE6.1, Raji, and DL cells were cultured in complete medium, with increasing concentrations of DOX up to a final concentration of 1 mM at 5% CO 2 , 37uC for one month. Resistant Cells were subsequently cloned by limiting dilution and grown in complete medium. The established cell lines were maintained in complete medium supplemented with 200 nM DOX to maintain the resistant phenotype. All DOX resistance cells were cultured in the DOX free medium for 14 days prior to experiments.
Preparation of DOX-PCL 63 -b-PNVP 90
DOX-loaded polymeric micelles were prepared by dialysis method. In the dialysis method, the copolymer PCL 63 -b-PNVP 90 (20 mg) was dissolved in DMF (2 ml), and a corresponding DOX?HCl (6 mg) with TEA (3 mol eq. to DOX?HCl) were added into the polymer solution. The mixture was stirred at room temperature for 24 h. Then, the final mixture was dialyzed against distilled water using a dialysis membrane [molecular weight cut off (MWCO) = 3500 g mol 21 ] for 8 h. During the first 3 h, the water was exchanged three times (every hour) and then twice during the following 5 h. The dialyzed solution was finally concentrated to 2 mL followed by lyophilisation to yield the solid micelle sample. Morphology and size of the micelles were determined by Transmission Electron Microscopy (TEM) (JOEL, JEM, 2100) operated at an acceleration voltage of 120 kV. The TEM samples were prepared by putting a drop of aqueous block copolymer solution (1 mg/mL) on the carbon coated copper grid followed by the removal of extra solution with a filter paper. The Dynamic Light Scattering Instrument (Malvern Zetasizer Ver. 7.01 Serial Number: MAL1077742) was performed to study the hydrodynamic size (Rh) of the free micelles and DOX-PCL 63 -b-PNVP 90 micelles using 0.5 mg/ml solution at 90 o angle.
Determination of Drug-loading Content (DLC) and Drugloading Efficiency (DLE) for DOX
The DLC was considered as the weight percentage of DOX in the micelle. It was quantified by determining the absorbance at 451 nm using a UV-Vis spectrophotometer (Shimadzu UV-1700). 1 mg of lyophilized sample was dissolved in 2 mL DMF for the UV-Vis measurement. To generate a calibration curve for the DLC calculation of DOX-loaded micelle, DOX solutions of various concentrations were prepared, and the absorbance at 485 nm was measured. DLC and DLE are calculated using the following two formula respectively:Drugloadingcontent(DLC)wt%W eight of drug load Weight of polymer |100, Drugloadingefficiency(DLE)%W Typical Drug Release from DOX-PCL 63 -b-PNVP 90 Micelles 5 mg of lyophilized DOX-loaded polymeric micelle dissolved in 1 ml phosphate buffer saline (PBS) of 6.4/7.4 pH was taken in a dialysis bag with a MWCO of 3500 g mol 21 , which was placed into 20 ml PBS solution. At different intervals, 3.0 ml was removed from the outer aqueous solution and replaced by fresh release medium (PBS solution). The released drug was quantified spectrophotometrically at 483 nm. The test was performed at 37uC. 
In-vitro Tumor Cell Growth Inhibition Assay
Clonogenic Survival Assay
The clonogenic survival assay was performed according to the method described by Nicolaas A P Franken et al. [17] with some modifications. Cells (10 mL from a stock (1610 4 cells/ml) were treated with 0.1 to 5.0 mM of the DOX-PCL 63 -b-PNVP 90 or, free DOX for 24 h. Cells treated with free micelles were used as control. The cells were washed, diluted in RPMI containing 10% (v/v) fetal calf serum, the supplements listed above, and 0.3% noble agar (Difco, Detroit, MI) and plated in 6-well plate in triplicate on soft agar. Once set, the dishes were overlaid with 1.0 ml complete medium and incubated at 37uC. After 10 days, the total number of colonies/plate was counted. Plating efficiency (PE) and surviving fraction (SF) were calculated as mean 
Intracellular DOX Release and Efflux Study
Murine Lymphoma Model
AKR/J mice were maintained and bred under pathogen-free condition of the central animal house facility of the department. Use of mice was approved by the Institutional Animal Ethics Committee, Banaras Hindu University. All animal experiments were performed according to the National Regulatory Guidelines issued by Committee for the Purpose of Supervision of Experiments on Animals (CPSEA), Ministry of Environment and Forest, Government of India. The animals were euthanized by cervical dislocation to reduce the suffering as minimum as possible and was performed according to AVMA Guidelines on Euthanasia (AVMA 2007). Tumors (DL) in mice were maintained by transplanting fresh tumor cells in PBS (3610 4 cells/mouse) intraperitoneally. All tumor measurements were performed in a blinded fashion. Mice (n = 15/group) were transplanted with tumor and after 96 h (Day 0) were treated with the DOX-PCL 63 -b-PNVP 90 micelles or, free doxorubicin in PBS and were administered intraperitoneally (3 mg kg -1 body weight). Mice treated with free micelles were used as control. Altogether 9 doses were given in two phases which includes 4 doses (from day 0 to day 4) given every day and remaining 5 booster doses were given from day 10 to day 20 at an interval of 48 h, respectively. The formulation was prepared and validated such that 100 ml of DOX-PCL 63 -b-PNVP 90 micelles contained 3 mg kg 21 body weight of DOX. PBS (100 ml) was used as vehicle control for drug treatment. The tumor volumes (abdominal circumference) and body weights were monitored on a daily basis. The animals (n = 3) were sacrificed when the average abdominal circumference of the control (PBS only) exceeded 15.5 cm. Before sacrifice, tumor cells were collected in the form of ascitic fluid from peritoneum and blood by retro orbital bleeding. Blood films were prepared, fixed (methanol) and stained with Leishman stain to study the effects of DOX on leukocytes. Organs (spleen, liver, heart, lung, and kidney) were dissected out & weighed. Organs were cut into three parts. One portion was preserved in 10% formalin for further analysis and the other two parts were weighed again for DOX distribution and flow cytometry studies. Mice (n = 12/group) were under observation for 50 days when final data collection was made for Kaplan Mayer survival analysis.
Doxorubicin Distribution in Various Organs after Therapy
The tissue blocks (1 mg) were homogenized in lysis buffer solution (50 mM Tris-HCL, 150 mM NaCl, 0.1% NP40, 0.1% SDS, 0.1% sodium deoxycholate, 1% Triton X-100). 
Tumor sample analysis
Formalin-fixed, paraffin-embedded primary tissues from liver, lung and spleen were obtained during therapeutic procedures from control, DL tumor bearing mice and the tumor bearing mice undergone indicated therapy. Hematoxylin and eosin-stained sections were examined for regions that contained tumor cells and stroma indicating the extent of metastasis. All studies were conducted using protocols approved by the Institutional Review Board of the University.
Apoptosis Study in Organs after Therapy
Evaluation of apoptotic cell death in tumor, spleen, liver and lung cells by free doxorubicin or, by DOX-PCL 63 -b-PNVP 90 micelles after therapy was assessed by binding FITC-conjugated Annexin V. In a single cell suspension of various organs, the percentages of FITC-conjugated Annexin V-positive cells were analyzed by BD FACS Calibur flow cytometer as described earlier (Beckton Dickinson, U.S.A.). For microscopic study, liver and spleen single cell suspension were washed with ice-cold PBS and stained with FITC-conjugated Annexin V and mounted on glass slides with a drop of mounting media to reduce fluorescence photo bleaching. The FITC-conjugated Annexin V positive cell and intracellular DOX localization were visualized under a fluorescence microscope (Nikon Eclipse 80i, Nikon, Japan).
Statistical Analysis
Flow cytometry data were analyzed using Flow-Jo software (version 10.0.5; Treestar, Ashland, OR, USA). The mean 6 SD were calculated for each experimental group (n = 3-5). Differences between groups were analyzed by unpaired Student's t-test and one-or two-way ANOVA analysis of variance depending on the requirement. One or two-way ANOVA followed by Holm-Sidak post-hoc multiple comparison tests was used to conduct pair wise comparisons using PRISM statistical analysis software (Graph Pad Software, Inc., San Diego, CA, USA). Significant differences among groups were calculated at P,0.05 or less (*P,0.05, **P,0.01, ***P,0.001, ****P,0.0001 in control versus experimental group). Statistical significance of differences in survival of the mice in different groups was determined by the log-rank test using Graph Pad PRISM software. 
Results and Discussion
The present study was motivated by the need to design a safe nano-carrier for the delivery of doxorubicin which could be tolerant to normal cells. PCL 63 -b-PNVP 90 [13] was loaded with doxorubicin (6 mg/ml), and with 49.8% drug loading efficiency; it offers a unique platform providing selective immune responses against lymphoma. The delivery system proved to be a novel strategy, preventing metastasis in a highly aggressive lymphoma besides maintaining a minimum cardiotoxicity.
Preparation and Characterization of Blank and DOX-PCL 63 -b-PNVP 90 Miceller Nanoparticle
Well-defined amphiphilic block copolymer PCL 63 -b-PNVP 90 containing hydrophobic PCL block made of 63 CL unit and Figure S1 A-C) . Loading of the drug in the micelle is evidenced by the increase in the size (TEM study) and hydrodynamic radius (Rh) (DLS study) of the drug-free micellar nanoparticle [from radius of 17 nm (TEM study) and hydrodynamic radius (Rh) of 42.5 nm (DLS study)] [13] towards the formation of the drug-loaded micellar nanoparticle [of radius of 24.5 nm (TEM study) and hydrodynamic radius (Rh) of 110 nm (DLS study)] ( Figure S1 E-F) . To study the effect of the pH of the release medium on the release kinetics of the drug from the drugloaded micellar nanoparticle, we have chosen two phosphate buffer saline (PBS) solutions of pH 6.4 and 7.4. As shown in Figure  S1 D, the observed DOX release (%) of drug loaded micelles at pH 7.4 and 6.4 are ,19% and ,37%, respectively. The drug release rate increases gradually up to initial 12 h and then becomes leveled off which may due to the strong interaction between drug and PCL hydrophobic block as well as due to the low solubility of the drug in the used PBS media. The observed rapid release of DOX loaded micelles at low pH is due to the presence of NH 2 functional group in DOX. So, the observed accelerated drug release at low pH solution can be considered as an advantage for the antitumor drug delivery system.
Growth Inhibition by DOX-PCL 63 -b-PNVP 90 in Lymphoma Cells
We performed 48 h growth inhibition study by the DOX-PCL 63 -b-PNVP 90 against parental and DOX-resistant human (K-562, JE6.1, Raji) and mice lymphoma cells (DL) (Figure 2 ). Compared to free doxorubicin (DOX), DOX-PCL 63 -b-PNVP 90 shows significantly higher growth inhibition in a concentration dependent manner against the cells tested. K-562 (6.6262.67 vs. 14.3961.23, p = 0.0227, n = 6), JE6.1 (11.2264.08 vs. 24.7762.69, p = 0.007, n = 6), and DL (9.5264.27 vs. 33.3662.32, p,0.0001, n = 6) responded better with significantly higher growth inhibition compared to free DOX (Figure 2 A, C , E, and G) above the doxorubicin concentration 0.01 mM. Raji appears to be little less sensitive although effect of DOX-PCL 63 -b-PNVP 90 is higher in Raji compared to free DOX (20.6460.625 vs. 31.2560.194, p = 0.022, n = 6) at DOX concentration of 0.5 mM ( Figure 2E) . Carrier it-self has no effect on growth inhibition in any of the cell line tested. DOX-resistant variants of the above cell lines (Figure 2 B, D, F, and H) . Free DOX unable to control the tumor cell growth at a concentration of 10 26 M, a concentration in which DOX-PCL 63 -b-PNVP 90 shows remarkably high growth inhibition of all the resistant variants tested. Biodegradable micelles based on amphiphilic block copolymers such as poly (e-caprolactone) (PCL) have emerged as one of the most promising nano system for controlled and site-specific delivery of potent lipophilic anticancer drugs like doxorubicin due to their proven biocompatibility and FDA approval for medical uses [18] [19] [20] [21] . Besides reducing drug induced side effects, these micelles enhance water solubility, bioavailability and increase drug accumulation in tumors via enhanced permeability and retention (EPR) effect [22] . Stimuli (pH, temperature etc.) sensitive biodegradable polymers have recently been developed with faster intracellular drug release feature in tumor cells and ability to reverse multidrug resistance (MDR) in cancer cells [23, 24] . Our data shows that DOX-PCL 63 -b-PNVP 90 works better in lower pH compared to higher pH suggesting its better suitability in acidic environment inside the tumor cells (Figure S1 D) . This was supported by the susceptibility of human and murine lymphoma cells against DOX-PCL 63 -b-PNVP 90 with respect to growth inhibition (Figure 2 ).
Cellular Cytotoxicity by DOX-PCL 63 -b-PNVP 90 in Lymphoma Cells
The growth inhibition data suggested that DOX-PCL 63 -b-PNVP 90 has significantly higher anti-tumor potential with respect to the reduction in the growth of lymphoma cells from human and mice. We wanted to know whether the growth inhibition is preceded by direct cytotoxicity of the tumor cells. Our results suggest that DOX-PCL 63 -b-PNVP 90 is highly cytotoxic compared to free DOX at each molar concentrations of DOX tested (mean increased toxicity and need for specific drug release rates during disease evolution [25] [26] [27] . Our formulation of DOX-PCL 63 -b-PNVP 90 shows significant growth inhibition and cytotoxicity against resistant variants of human and mice lymphoma cells, suggesting broad spectrum usefulness of the compound (Figures 2  and 3 ).
Cellular Uptake Studies
We generated DOX resistant K-562, JE6.1, Raji and DL by continuous culture of the tumor cells in medium containing IC 50 doses of DOX and selected to test the efficiency of DOX-loaded PCL 63 -b-PNVP 90 in overcoming the DOX resistance. DOX resistance was documented by the huge increase in the IC 50 doses of each cell lines and their tolerance to the doses of DOX, usually causes death of the non-resistant variants (Figures 2 and 3) . We next demonstrated whether DOX-PCL 63 -b-PNVP 90 can increase the drug accumulation and retention in normal and resistant variants of the cell lines tested. Free DOX or DOX-PCL 63 -b-PNVP 90 in culture medium was incubated with either resistant or parental variants of K-562, JE6.1, Raji or, DL at concentration of 2.0 mM of DOX for different time intervals from 0 to 30 h. The medium was discarded by washing in PBS and intracellular DOX accumulation was determined by analyses of DOX concentration in the cell lysates, which were normalized to total cellular protein content of the cells. It should be mentioned that the fluorescence intensity of DOX loaded PCL 63 -b-PNVP 90 was similar to that of pure DOX at the same pH and molar concentration. Figure 4 E-H, the DOX incorporation was significantly higher in all the cell lines tested confirming our quantitative determination of DOX incorporation. With DOX-resistant variants, we observed similar results as described by uptake studies (data not shown). We extended our observation of DOX-uptake at microscopic level for visualizing the presence of significantly higher DOX concentration intracellularly in K-562 and DL. As observed in Figure 4I and 4J, the intracellular level of DOX is significantly higher in cells treated with DOX-PCL 63 -b-PNVP 90 compared to free DOX suggesting high drug delivery efficiency of the compound.
Internalization and Intracellular Drug Release Behavior of DOX-PCL 63 -b-PNVP 90
We next demonstrated that DOX could be released from DOX-PCL 63 -b-PNVP 90 in response to the intracellular acidic microenvironment during or after its accumulation in tumor cells. Endocytosis is known as one of the important entry mechanisms for various extracellular materials, particularly nanoparticles, which is energy dependent and can be hindered when incubation is performed at low temperatures (e.g., 4uC instead of 37uC) [28] . We found that free DOX demonstrate significantly higher release behavior compared to DOX-PCL 63 -b-PNVP 90 ( Figure S2 ). We also studied the DOX release pattern in normal cells like lymphocytes and purified dendritic cells (DC). Our results suggest that intracellular DOX concentration rises to its maximum levels (14.2161.382 mM) between 5-10 h and drop very sharply to a level as low as 3.560.320 mM ( Figure S3) . Surprisingly lympho- 
Clonogenic Survival Assay
In addition to the rapid Annexin V assay, a clonogenic survival assay was also employed to assure that we were detecting a true commitment to die and not just early, potentially reversible, changes in the cells treated with either DOX or DOX-PCL 63 -b-PNVP 90 . Our results suggest that with DOX-PCL 63 -b-PNVP 90 treatment, the number of colonies of DL cells become negligible compared to free DOX ( Figure 7A-D) . Analysis of survival fraction suggest that with DOX-PCL 63 -b-PNVP 90 treatment, there is a sharp decline compared to free DOX at a concentration of 1-2 mM of DOX ( Figure 7E ).
In Vivo Antitumor Activity
Therapeutic efficacy of DOX-PCL 63 -b-PNVP 90 was validated in DL tumor model. Randomly sorted mice (female, 4-6 weeks old) were transplanted with tumor intraperitoneally and were sorted in to 4 groups each with 12 mice and treated with 4 daily injections of (i) phosphate buffer saline (PBS) (ii) free doxorubicin (3 mg/kg of body weight), (iii) vehicle control or (iv) DOX-PCL 63 -b-PNVP 90 (equivalent to 3 mg/kg of doxorubicin dose) after 96 hours post tumor challenge (marked as day 0). A second set of 5 injections were given to the animals from day 10 to day 18 with a gap of 48 h ( Figure 8A ). The mice injected with PBS or, vehicle control formed large intraperitoneal ascitis by day 12 post tumor transplant, which continued with increasing size as the day progresses. Mice treated with free DOX also develops tumor and forms similar ascitis at day 20. In contrast, mice treated with DOX-PCL 63 -b-PNVP 90 develops tumor at a significantly slower rate and develops tumor at day 30. All the mice in PBS and vehicle control groups died between day 22 and 24 from tumor progression. Mice in free doxorubicin group did not survive beyond the day 32. In contrast, 4 of 12 mice in the DOX-PCL 63 -b-PNVP 90 group were alive at day 50 when the experiment was doses, 4 doses were given every day (from day 0 to Day 4) and remaining 5 dose were given from day 10 at an interval of 48 h and continued up to day 18. The animals in study responded to the therapy with DOX-PCL 63 -b-PNVP 90 (B). Kaplan-Mayer survival analysis of tumor bearing mice was performed following therapy and was analyzed for the percent survival up to day 50 post tumor transplant by log-rank test using Graph Pad PRISM software (C). Abdominal circumference (D) and body weight (E) are depicted demonstrating the effects of the treatment on the tumor growth of the animals. Representative images of spleen, liver, heart, lung, and kidney from each treatment group (F) and the corresponding weight of excised organ following drug treatment compared to untreated control are shown (G) n = 3. doi:10.1371/journal.pone.0094309.g008
Efficacy of DOX-PCL63-b-PNVP90 Micelle System in Treating Lymphoma 90 and effect of tumor derived carboxylesterases could be responsible for release of doxorubicin and reduces its systemic toxicity [29] . Histopathological analysis of liver, lung and spleen clearly indicates the efficacy of the formulation in restricting the metastasis of the organs ( Figure 9A ). In liver, infiltrated metastatic lymphoid cell (red circle) are clearly visible in DL mice which are significantly reduced in mice treated with DOX-PCL 63 -b-PNVP 90 . Similarly, in lung normal architecture is lost due to tumor metastasis which is accompanied by the recruitment of neutrophils (red arrow) and evidence of haemorrhage and necrosis (yellow Apoptosis observed in liver and spleen cells presented in Figure  S5C are the mainly in tumor cells present in liver and spleen. No observable apoptosis was observed in control group. In case of DOX loaded micelle group, much more apoptosis is observed in tumor bearing mice. This is further supported by Figure S6 , where we observe that free DOX causes cell death in normal mice spleen, liver and lung, significantly higher compared to DOX loaded polymer (normal mice were treated with free DOX or DOX loaded polymer). This indicates the general toxicity of free DOX while DOX-PCL 63 -b-PNVP 90 remain significantly less toxic.
Conclusion
In this study, we have demonstrated the potential application of doxorubicin-loaded poly (e-caprolactone)-b-poly-(N-vinylpyrrolidone) micellar nano-carrier in cancer chemotherapy. Several components of this platform make it an attractive approach for facilitating future therapy in humans. Hydrophilic exterior and hydrophobic interior of our formulation offers entrapment of higher concentrations of doxorubicin to form micelles and get easy access through the cells leading to high efficiency of cellular uptake by endocytosis and subsequent acid responsive release in tumor cells. Assay with normal cells indicates reduced toxicity to WBCs and vital organs like heart while maintaining higher therapeutic efficacy, compared to commercial doxorubicin hydrochloride. DOX-PCL 63 
